Children with Severe Infection of Gram-Positive Bacteria:
Conditions
Interventions
Group 1:Continuous vancomycin infusions
Group 2:intermittent vancomycin infusion
Sponsors
Capital Institute of Pediatrics
Eligibility
Sex/Gender
All
Age
0.1 Years to 14 Years
Inclusion criteria
Inclusion criteria: 1. Children aged 1 to 144 months requiring vancomycin therapy will be considered regardless of sex, religion or nationality. during June 1, 2017 to June 1, 2020; 2. Hospitalized patients over 1 month-old in intensive care unit; 3. Serious infection caused by Gram-positive bacteria was suspected or confirmed by clinical symptoms, signs and laboratory tests, and there are indications for the treatment of vancomycin.
Exclusion criteria
Exclusion criteria: 1. Known glycopeptide allergy; 2. Renal impairment before vancomycin treatment; 3. Infants receiving vancomycin or other glycopeptide administration such as norvancomycin, teicoplanin, linezolid and rifampicin within the previous 72 hours, for more than 24 hours; 4. The drugs had a synergistic effect which affects the judgment of curative effect; 5. The combination of drugs with nephrotoxicity affects the safety assessment; 6. Extracorporeal membrane oxygenation, continuous renal replacement therapy; 7. The guardian refused to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood concentration of vancomycin; | — |
Countries
China
Contacts
Public ContactDong Qu
Capital Institute of Pediatrics
Outcome results
None listed